The Cutaneous Oncology and Melanoma Program seeks to generate new discoveries in molecular pathogenesis, tumor-host interactions, therapeutic interventions and in the influence of the environment on melanoma development.
The specific aims of the Program are to: 1) investigate the molecular pathogenesis of melanoma from discovery to clinical application, 2) explore tumor-host interactions as opportunities for therapeutic intervention and 3) investigate the unique influences of the environment on the development of melanoma. The Program is presented for the first time as an Established Research Program. It is comprised of 37 members from six DF/HCC institutions who have expertise in epidemiology, dermatology, oncology, dermatopathology, surgical oncology, radiation oncology, laboratory science, clinical trials and outcomes analyses. Members are engaged in molecular studies, developmental biology, genetics, melanoma immunology and molecular genetics. All share a common interest in the prevention and treatment of skin cancers and convene regularly through a clinical trials group, laboratory science meetings and annual Program retreats. DF/HCC provides the infrastructure needed to facilitate interdisciplinary, inter-institutional translational research and to facilitate inter-programmatic collaborations. Successes to date includes the identification of several key melanoma signaling pathways, genomic loci, oncogenes, and clinical strategies. The Program has produced a significant collection of publications covering multiple aspects of melanoma biology (244) during the project period of which 9% were intra-programmatic, 56% were inter-programmatic and 36% were inter-institutional manuscripts. In 2009, the Cutaneous Oncology and Melanoma Program had $9.2 million in peer-review funding, of which $5 million was from NCI.

Public Health Relevance

Melanoma is ranked as one of the top ten deadliest cancers. Approximately 68,720 melanomas will be diagnosed this year, with nearly 8,650 resulting in death. While death rates for most cancers are declining, the number of new cases of melanoma has continued to increase, with an estimated number of 68,720 new cases in 2009. Continued investigations into the mechanisms that initiate and drive the growth of skin cancers will ultimately result in the development of innovative new approaches for cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601454
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$74,963
Indirect Cost
$60,778
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications